Corporate Presentation May 2022 Resmetirom is an investigational therapy and has not been approved by the FDA (or any other regulatory authority). Resmetirom is only available for use in a clinical trial setting (ClinicalTrials.gov NCT03900429, NCT04197479). NASDAQ: MDGL © 2022 Madrigal Pharmaceuticals. All rights reserved. Forward Looking Statements This communication contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, t ...